Evidence map›Paper›PMID 36483197›Full record

ArticleFrontiers in microbiology2022

Gut microbiota profile of COVID-19 patients: Prognosis and risk stratification (MicroCOVID-19 study).

José Guilherme Nobre, Mariana Delgadinho, Carina Silva, Joana Mendes, Vanessa Mateus, Edna Ribeiro, Diogo Alpuim Costa, Miguel Lopes, Ana Isabel Pedroso, Frederico Trigueiros and 3 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Editorial: Gut microbiota in health and disease.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

José Guilherme NobreFaculty of Medicine, Lisbon University, Lisbon, Portugal.
Mariana DelgadinhoH&TRC- Health and Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal.
Carina SilvaH&TRC- Health and Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal.
Joana MendesH&TRC- Health and Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal.
Vanessa MateusH&TRC- Health and Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal.
Edna RibeiroH&TRC- Health and Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal.
Diogo Alpuim CostaBreast Cancer Unit, CUF Oncologia, Lisbon, Portugal.
Miguel LopesDepartamento de Pneumologia, Hospital Garcia de Orta, Almada, Portugal.
Ana Isabel PedrosoServiço de Medicina Intensiva, Hospital de Cascais Dr. José de Almeida, Cascais, Portugal.
Frederico TrigueirosDepartamento de Medicina Interna I, Centro Hospitalar Lisboa Norte - Hospital de Santa Maria, Lisbon, Portugal.
Maria Inês RodriguesDepartamento de Medicina Interna I, Centro Hospitalar Lisboa Norte - Hospital de Santa Maria, Lisbon, Portugal.
Cristina Lino de SousaDepartamento de Medicina Interna, Hospital da Luz, Lisbon, Portugal.
Miguel BritoH&TRC- Health and Technology Research Center, ESTeSL- Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gut microbiota is intrinsically associated with the immune system and can promote or suppress infectious diseases, especially viral infections. This study aims to characterize and compare the microbiota profile of infected patients with SARS-CoV-2 (milder or severe symptoms), non-infected people, and recovered patients. This is a national, transversal, observational, multicenter, and case-control study that analyzed the microbiota of COVID-19 patients with mild or severe symptoms at home, at the hospital, or in the intensive care unit, patients already recovered, and healthy volunteers cohabiting with COVID-19 patients. DNA was isolated from stool samples and sequenced in a NGS platform. A demographic questionnaire was also applied. Statistical analysis was performed in SPSS. Results: Firmicutes/Bacteroidetes ratios were found to be significantly lower in infected patients (1.61 and 2.57) compared to healthy volunteers (3.23) and recovered patients (3.89). Furthermore, the microbiota composition differed significantly between healthy volunteers, mild and severe COVID-19 patients, and recovered patients. Furthermore Conclusion: We can conclude that microbiota composition is significantly affected by SARS-CoV-2 infection and may be used to predict COVID-19 clinical evolution. Therefore, it will be possible to better allocate healthcare resources and better tackle future pandemics.

Indexed as

COVID-19dysbiosismicrobiomemicrobiotanext generation sequencingprognosisrisk stratification

Identifiers

PMID36483197
PMCPMC9723140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.